Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library
Research-use-only peptides and FDA 503A/503B law
What "not for human consumption" means and how compounding law treats peptides
Evidence verdict: Based on FDA primary documents. Legal status depends on the specific substance and changes over time; check the live FDA lists.
Last reviewed: Oct 27, 2026
In 30 seconds
- A "research use only" label does not make a product legal or safe to use in people, and it means the product has had no FDA review for human use. [Regulatory]
- Pharmacies compound under section 503A; outsourcing facilities under 503B. Each can only use bulk substances that meet the law's criteria or are on FDA's lists. [Regulatory]
- FDA lists several peptides, including BPC-157, thymosin alpha-1 and ipamorelin, as bulk substances that may present significant safety risks, citing immunogenicity and peptide-related impurities. [Regulatory]
- FDA says compounded drugs should be used only when an FDA-approved drug cannot meet a patient's medical needs. [Regulatory]
Three different things
An FDA-approved drug has been reviewed for safety, effectiveness and quality. A compounded drug is made by a licensed pharmacy (503A) or registered outsourcing facility (503B) for patients, under conditions in the FD&C Act, and is not FDA-approved. A "research use only" product is sold outside both systems and is not intended for people. [Regulatory]
The bulk substance lists
FDA maintains bulk drug substance lists and categories for 503A and 503B (FDA bulk drug substances page). [Regulatory] Its safety-risk page (content current as of 04/22/2026) says compounded drugs containing BPC-157 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities", and gives similar reasons for thymosin alpha-1 and ipamorelin acetate. [Regulatory] Status for any one peptide should be checked on the live lists before publication.
Compounded GLP-1 drugs
FDA's page on unapproved GLP-1 drugs (content current as of 10/01/2026) says unapproved versions do not undergo FDA review for safety, effectiveness and quality, that compounded drugs should only be used when an approved drug cannot meet a patient's needs, and that patients should fill prescriptions at state-licensed pharmacies. [Regulatory]
Recent professional analysis
A 2026 review in the International Journal of Pharmaceutical Compounding examined the Pharmacy Compounding Advisory Committee's recommendations on synthetic peptides and their practical implications for compounders (PMID 42752426). [Observational, review]
What this page does not cover
State pharmacy law, import rules and enforcement history vary and are not summarized here (UNVERIFIED). This is not legal advice.
Evidence levels used on this page
- [Regulatory] FDA, USP or WADA primary document. [Controlled study] randomized trial or systematic review of trials. [Observational] market surveillance, pharmacovigilance or cohort data. [Lab] cell, analytical or animal work. [Case] single case report.
Related
Counterfeit and mislabeled gray-market peptides, WADA Prohibited List and peptides
References
- US FDA. Bulk drug substances used in compounding (503A and 503B lists). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding
- US FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 04/22/2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- US FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of 10/01/2026). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Willis et al. Synthetic peptides in pharmacy compounding: analysis of PCAC recommendations and industry safety standards. Int J Pharm Compd. 2026. PMID 42752426.
Disclaimer: This page is for education only. It is not medical advice, and it does not endorse using, buying or preparing any unapproved product. Talk to a licensed clinician before you start, stop or change any treatment.